| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
T Cells by Administering a Daunomycin-Conjugated Specific Monoclonal Antibody in Early Tumor Lesions Augments the Activity of CTLs and NK Cells1
*
Department of Tumor Biology, Institute of Medical Science, University of Tokyo, Minatoku, Tokyo, Japan; and
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
It has been demonstrated that 
T cells accumulating in early
tumor lesions and those purified from spleen cells of tumor-bearing
mice attenuate the activity of CTLs and NK cells. We, therefore,
investigated whether depletion of T cells from early lesions of
tumors results in restoration of CTL and NK cell activities and
subsequent regression of tumors. A daunomycin-conjugated
anti-TCR mAb UC7-13D5 (Dau-UC7) was prepared to efficiently
deplete T cells. An in vitro study revealed that Dau-UC7
specifically lysed TCR+ cells and effectively
inhibited splenic T cells from tumor-bearing mice to produce
cytotoxic cell-suppressive factors. Furthermore, intralesional
injections of Dau-UC7 at an early stage of tumor development led to
augmentation of tumor-specific CTL as well as NK cell activities and to
the resultant regression or growth inhibition of the tumors. On
analysis of cytokine profile, T cells transcribed mRNAs for
IL-10 and TGF-ß, but not IL-4 or IFN-, suggesting the T regulatory
1-like phenotype. Finally, a blocking study with mAbs showed that the
inhibitory action of T cells on CTLs and NK cells was at least
partly mediated by IL-10 and TGF-ß. These results clearly
demonstrated the novel mechanism by which T regulatory 1-like T
cells suppress anti-tumor CTL and NK activities by their regulatory
cytokines in early tumor formation.
This article has been cited by other articles:
|
|
 |
|
  T. Fujita, K. Teramoto, Y. Ozaki, J. Hanaoka, N. Tezuka, Y. Itoh, T. Asai, S. Fujino, K. Kontani, and K. Ogasawara Inhibition of Transforming Growth Factor-{beta}-Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell Types Cancer Res., June 15, 2009; 69(12): 5142 - 5150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L Davis and J. L Pate Bovine Luteal Cells Stimulate Proliferation of Major Histocompatibility Nonrestricted Gamma Delta T Cells Biol Reprod, December 1, 2007; 77(6): 914 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Ashour and J. Y. Niederkorn {gamma}{delta} T Cells Promote Anterior Chamber-Associated Immune Deviation and Immune Privilege through Their Production of IL-10 J. Immunol., December 15, 2006; 177(12): 8331 - 8337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bellone, A. Carbone, C. Smirne, T. Scirelli, A. Buffolino, A. Novarino, A. Stacchini, O. Bertetto, G. Palestro, C. Sorio, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J. Immunol., September 1, 2006; 177(5): 3448 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wu, A. Ootani, R. Iwakiri, Y. Sakata, T. Fujise, S. Amemori, F. Yokoyama, S. Tsunada, S. Toda, and K. Fujimoto T Cell Deficiency Leads to Liver Carcinogenesis in Azoxymethane-Treated Rats Experimental Biology and Medicine, January 1, 2006; 231(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Rogers, D. G. VanBuren, E. E. Hedblom, M. E. Tilahun, J. C. Telfer, and C. L. Baldwin {gamma}{delta} T Cell Function Varies with the Expressed WC1 Coreceptor J. Immunol., March 15, 2005; 174(6): 3386 - 3393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Castriconi, C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells PNAS, April 1, 2003; 100(7): 4120 - 4125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. X. Zhu, S. Sharma, B. Gardner, B. Escuadro, K. Atianzar, D. P. Tashkin, and S. M. Dubinett IL-10 Mediates Sigma1 Receptor-Dependent Suppression of Antitumor Immunity J. Immunol., April 1, 2003; 170(7): 3585 - 3591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mazzoni, V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism J. Immunol., January 15, 2002; 168(2): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Oelmann, H. Herbst, M. Zuhlsdorf, O. Albrecht, A. Nolte, C. Schmitmann, O. Manzke, V. Diehl, H. Stein, and W. E. Berdel Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells Blood, January 1, 2002; 99(1): 258 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Skelsey, J. Mellon, and J. Y. Niederkorn {{gamma}}{{delta}}T Cells Are Needed for Ocular Immune Privilege and Corneal Graft Survival J. Immunol., April 1, 2001; 166(7): 4327 - 4333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. X. Zhu, S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett {Delta}-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway J. Immunol., July 1, 2000; 165(1): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
